Repository logo
 

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.

cam.issuedOnline2021-12-22
dc.contributor.authorBarca, Cristina
dc.contributor.authorGriessinger, Christoph M
dc.contributor.authorFaust, Andreas
dc.contributor.authorDepke, Dominic
dc.contributor.authorEssler, Markus
dc.contributor.authorWindhorst, Albert D
dc.contributor.authorDevoogdt, Nick
dc.contributor.authorBrindle, Kevin
dc.contributor.authorSchäfers, Michael
dc.contributor.authorZinnhardt, Bastian
dc.contributor.authorJacobs, Andreas H
dc.contributor.orcidBarca, Cristina [0000-0001-8034-2948]
dc.contributor.orcidDevoogdt, Nick [0000-0001-9220-4833]
dc.contributor.orcidBrindle, Kevin [0000-0003-3883-6287]
dc.contributor.orcidZinnhardt, Bastian [0000-0002-8274-9108]
dc.date.accessioned2022-01-07T16:47:53Z
dc.date.available2022-01-07T16:47:53Z
dc.date.issued2021-12-22
dc.date.updated2022-01-07T16:47:53Z
dc.description.abstractRadioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
dc.identifier.doi10.17863/CAM.79788
dc.identifier.eissn1424-8247
dc.identifier.issn1424-8247
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/332342
dc.languageen
dc.publisherMDPI AG
dc.subjecttheranostics
dc.subjecttumor
dc.subjectgene therapy
dc.subjectcell-based therapy
dc.subjectmolecular imaging
dc.subjectpositron emission tomography
dc.subjectradiopharmaceuticals
dc.titleExpanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
dc.typeArticle
dcterms.dateAccepted2021-12-16
prism.issueIdentifier1
prism.publicationNamePharmaceuticals (Basel)
prism.volume15
pubs.funder-project-idEuropean Commission Horizon 2020 (H2020) Societal Challenges (831514)
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/ph15010013

Files

Original bundle
Now showing 1 - 3 of 3
No Thumbnail Available
Name:
pharmaceuticals-15-00013.xml
Size:
12.24 KB
Format:
Extensible Markup Language
Description:
Bibliographic metadata
Licence
https://creativecommons.org/licenses/by/4.0/
No Thumbnail Available
Name:
additional-files.zip
Size:
337.34 KB
Format:
ZIP file
Description:
Supporting information
Licence
https://creativecommons.org/licenses/by/4.0/
Loading...
Thumbnail Image
Name:
pharmaceuticals-15-00013.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/